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ABSTRACT We have identified a protein motif, related to
the zinc ringer, which dermes a newly discovered family of
proteins. The motif was found in the sequence of the human
RINGI gene, which is proximal to the major histocompatibility
complex region on chromosome six. We propose naming this
motif the "RING ringer" and it is found in 27 proteins, all of
which have putative DNA binding functions. We have synthe-
sized a peptide corresponding to the RING1 motif and exam-
ined a number ofproperties, including metal andDNA binding.
We provide evidence to support the suggestion that the RING
finger motif is the DNA binding domain of this newly defined
family of proteins.
Protein-DNA interactions are involved in many of the fun-
damental processes that occur inside cells, including tran-
scription, replication, recombination, and restriction. To
meet such a large number of functional requirements, a
number of protein sequence and/or structural motifs have
evolved that allow both specific and nonspecific DNA inter-
action (1, 2). Among these motifs are zinc fingers, which are
autonomously folding domains that require zinc for folding
and DNA binding activity (3, 4).
The classic zinc finger motif is characterized by two
conserved cysteines and histidines, which bind tetrahedrally
to a zinc atom thereby stabilizing the secondary structure
comprising an antiparallel two-stranded S-sheet and an a-he-
lix (5, 6). The N-terminal end of the a-helix is responsible for
makingDNA sequence-specific interactions, with each finger
recognizing 3 bp (7) as suggested previously (8). A second
class of zinc finger has been described in the steroid/nuclear
receptor family of proteins, which differs from the classic
zinc finger in that the motif binds two zinc atoms to form a
single folded domain with four cysteine ligands for each zinc
(for review, see ref. 9). The mode ofDNA interaction of this
motif differs from that of the classic zinc finger in that the
receptor binds as a dimer to a palindromic DNA sequence
(10). However, sequence-specific DNA interactions are
achieved by placing an a-helix in each of the major grooves
ofthe DNA site (10). Recently, a third class of zinc finger fold
has been described in the GAL4 DNA binding domain
(11-13). GAL4 binds two zinc atoms through six cysteines,
with the metals sharing two of the ligands (14). GAL4 also
uses an a-helix in the major groove for sequence-specific
DNA binding (11), which appears to be a common feature of
the three zinc-mediated folds characterized to date.
Previously, we have reported the identity ofa cysteine-rich
motiffound in the sequence ofthe RING] gene that is related
to the zinc finger (15). Here, we report the full sequence of
the human RING] gene and define further this motif, which
we propose to call the "RING finger." We extend the family
of proteins containing the motif and characterize a synthetic
peptide corresponding to the motif from RING1 in terms of
zinc and DNA binding.tt
MATERIALS AND METHODS
DNA Sequencing. Sequencing reactions were performed by
the primed synthesis chain-termination method using the
Sequenase 2.0 enzyme (United States Biochemical) directly
from plasmid DNA. The sequence was obtained from the
double-stranded cDNA and genomic subclone (first 90 bp),
with primers specific to the vectors and inserts.
Cells. All cell lines were obtained from the cell production
unit at the Imperial Cancer Research Fund. The following cell
lines were used: T cells, HSB.2, Molt-4, and J6; B cells,
Namalva, Mann, ROF-NL, and IM9; macrophage, U937;
cervical carcinoma, HeLa; fibroblast, HFF; embryonic lung,
ICRF-23; erythroid, K562.
RNA Isolation and Northern Blot Analysis. Poly(A)+ RNA
was isolated from cell lines with FastTrack (Invitrogen, San
Diego). After blotting the RNA onto Hybond N (Amersham),
the membrane was hybridized at 42°C to 32P-labeled RING]
(Multiprime; Amersham; 850-bp Xba I fragment) in 50%o
formamide, 5 x standard saline phosphate EDTA/5 x Den-
hardt's solution/0.1% SDS/100 ,ug ofsalmon sperm DNA per
ml, and washed at 65°C to a stringency of 0.1 x standard
saline citrate. The filter was exposed to autoradiographic film
at -70°C with intensifying screens.
Multiple Sequence Alignment of the RING Finger Family.
The RING1 amino acid sequence was used to search the
OWL14.0 protein data base with the program PROSRCH (16)
on an AMT-DAP computer. The RING finger motif was
further refined by using the pattern searching program PRO-
MOT (17). The sequence alignment was obtained automati-
cally by using the program package AMPS (18) with a point
accepted mutation matrix of 250 and a gap constant of 12.
Peptide Synthesis and Purification. The 55-amino acid pep-
tide corresponding to the RING1 motif (residues 12-66 in the
RING1 sequence) was synthesized on a model 430A Applied
Biosystems solid-phase synthesizer. The peptide was puri-
fied by reverse-phase preparative HPLC on a Brownlee
Aquapore ODS C18 column. A few milligrams of the pure
synthetic peptide was analyzed by electrospray mass spec-
trometry (19). To further characterize the synthetic product,
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=5 mg of freeze-dried peptide was reduced and alkylated by
the addition of 20 mM iodoacetic acid. Approximately 100
pmol of this material was covalently attached to an arylamine
membrane (20) and sequenced for 37 cycles by solid-phase
Edman degradation. The observed partial sequence was in
exact agreement with that expected from the synthesis, with
all expected cysteines positively identified as the correspond-
ing S-carboxymethyl derivatives. Reduced RING1 peptide
was prepared by the method described by Frankel et al. (21),
which involved treating the peptide with 250mM dithiothrei-
tol (DTT) at 90°C for 30 min. The reduced RING1 peptide was
stored at -20°C after removal of the DTT and lyophilization
and was used for all subsequent experiments.
Binding of Cobalt and Zinc to the RING1 Peptide. A solution
of peptide (1 ml) containing 160 MM reduced RING1 peptide
(10mM Tris+HCl, pH 7.0) was titrated with solutions ofCoCl2
in the same buffer. The peptide was also titrated against
solutions of ZnCl2, MnCl2, CdCl2, CuS04, MgSO4, and
FeSO4 in the presence of 100 ,uM CoCl2. The binding reaction
was monitored on an HP 8452 diode array spectrophotometer
using a 1-cm path length at room temperature, and each
spectrum was the average of three recorded spectra.
CD and NMR of the RING1 Peptide. The CD spectra
comprise the unsmoothed averages of four scans recorded in
a 0.1-mm quartz cuvette on a Jasco J-600 spectropolarimeter
using an instrumental time constant of 1 sec. The reduced
RING1 peptide (0.75 mg/ml) was dissolved in 50mM NaClO4
(pH 7.0) and the spectra were recorded in the absence and
presence of 2mM Zn2+. The spectrum obtained at 1 mM Zn2+
(data not shown) was effectively identical to that recorded in
the presence of 2 mM Zn2+. Secondary structure predictions
from the CD spectra were performed by the method of
Hennessey and Johnson (22). For the NMR experiments, the
reduced RING1 peptide (=200 ,uM) was dissolved in a 2H20
solution containing 10mM sodium phosphate, 50mM sodium
perchlorate, 100 MuM DTT, and 200 MuM EDTA (p2H 7.1)
(uncorrected meter reading). Argon was bubbled through the
solution to maintain a reduced environment. Data were
recorded on a Varian Unity 600 MHz spectrometer at 25°C.
DNA Binding of the RING1 Peptide. The reduced RING1
peptide was resuspended in phosphate-buffered saline and
diluted to 0.5 mg/ml in binding buffer [50 mM Hepes, pH
7.5/50 mM KCI/10% (vol/vol) glycerol/0.5 mM ZnSO4] with
1 mM DTT. The DTT was removed by dialysis against the
binding buffer. The binding reactions were carried out in 13 Al
of the binding buffer with 2 or 4 Ag of peptide/5 mM spermi-
dine/l mM EDTA/0.5% Nonidet P-40/6.25 Mg of bovine
serum albumin/various concentrations of poly(dIdC) and
32P-labeled DNA (76-bp oligonucleotide R76; ref. 23). The
peptide was preincubated with the nonspecific competitor
poly(dIdC) for 10 min at room temperature before the addition
of labeled DNA and a further 50-min incubation. As a control,
200 pg of the labeled DNA was incubated as described above
but without the peptide. The binding reactions were then run
on 0.5 x TBE ( x TBE = 90mM Tris/64.6mM boric acid/2.5
mM EDTA, pH 8.3)/10% polyacrylamide gels at 8 mA. The
gels were dried and autoradiographed for differing times on
Kodak XAR-5 film at room temperature.
RESULTS AND DISCUSSION
The RING1 Motif. The RING) gene was identified in
association with a CpG island at the centromeric end of the
human major histocompatibility complex on chromosome
6p21.3 and maps 95 kb proximal to the HLA-DPB2 gene (24).
The predicted amino acid sequence of RING1 (377 amino
acids; Fig. 1A) shows a glycine-rich region (27%) in the
C-terminal two-thirds and a cysteine-rich domain (residues
15-64) found near the N terminus. A putative nuclear local-
ization signal (KRPR) is also found associated with the
N-terminal cysteine-rich domain (25). Northern blot analysis
of the RING1 mRNA (Fig. 1B) shows that the gene is
expressed at similar levels in a variety of cell lines as a 1.6-kb
transcript, which correlates well with the predicted cDNA
sequence without a poly(A)+ tail. Initial protein sequence
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FIG. 1. (A) Nucleotide and predicted amino acid sequence of the
RING] gene. Cys and His residues constituting the RING finger
motif are indicated, as is the presence of a putative nuclear local-
ization signal (KRPR). Nucleotides shown in lowercase letters were
sequenced on one strand only. (B) Northern blot analysis of RING]
gene. GAPDH probe shows relative amounts of each RNA.
117
4
74
33
261
641Z
91
4 35
49
609
696
il 3
,80
65
:94
1044
33
31
-35_
305
'I 39-
1479
529
Biochemistry: Lovering et al.
2114 Biochemistry: Lovering et al.
searches using the N-terminal 139 residues identified se-
quences that contained a conserved cysteine-rich domain
(15). Subsequent searches combined with a review of recent
sequences identified 27 proteins that contained the motif (Fig.
2). The extended motif, which we propose to name the RING
finger, can now be summarized as Cys'-Xaa-hydrophobic
aa-Cys2-Xaa9-27-Cys3-Xaal-3-His-Xaa-hydrophobic aa-Cys4-
Xaa2-Cys5-hydrophobic aa-Xaa5.47-Cys6-Xaa2-Cys7.
The Cys and His residues are absolutely conserved in all of
the RING finger family (Fig. 2). Further conservation of
sequence is observed one residue before Cys2, Cys3, Cys4,
and Cys7 and one residue after Cys5, Cys6, and Cys7. These
amino acids are generally hydrophobic, with notable prefer-
ences for Phe before Cys4 and for Pro after Cys6. All of the
conserved residues may be important in secondary and
tertiary structure interactions and in positioning and orienting
the metal binding ligands. Four members of the family show
insertions of generally small amino acids between Cys3 and
the central His residue (Fig. 2). The average length ofthe first
"loop" (11±laa) excluding the two Baculovirus sequences
(CG30 and PE38) is similar to that of the second loop
(10±3aa) excluding the T18 sequence. Thus, the motif could
be reviewed as partially symmetric, which is a common
structural arrangement for many protein-DNA binding mo-
tifs. However, greater variation in length and sequence
conservation is observed within the second loop. Interest-
ingly, the RING finger motif generally occurs near the N
termini of member proteins.
Similarity of the RING Finger to Other Zinc Finger-like
Motifs. A comparison of the RING finger with the consensus
zinc finger motif shows that the first part of both motifs-
namely, XaarCys1-Xaa2-Cys2-Xaall_1-Cys3-are similar. A
number of hydrophobic residues are conserved between both
motifs (Fig. 2), and the lengths of the loop regions are also
similar (12aa for a consensus zinc finger). However, the RING
finger cannot be viewed simply as a motif of two tandemly
linked zinc fingers, as the central linking region between both
fingers would be too small and is probably involved in zinc
binding. The RING finger motifis also similar to the two-metal
binding motif ofglucocorticoid and estrogen receptor proteins
(9). Although the spacing ofthe metal ligands is different, there
are common features to both motifs, including the different
sizes of the two loops and the requirement for two zinc atoms
to form a single folded domain.
The most similar motif to the RING finger consensus
sequence is the LIM domain (26). The domain is found in a
number of homeodomain-containing proteins from Cae-
norhabditis elegans as well as in rat insulin I gene enhancer
binding protein (27). Although the LIM and RING motifs
appear similar in terms of cysteine spacings, there is no
sequence homology between both consensus sequences. In-
terestingly, the LIM motif has recently been shown to bind
both iron and zinc (28), although the domain has not been
shown to bind to DNA. It remains to be seen whether the LIM
and RING finger domains have any functional similarity.
The RING Finger Family. A common feature of the RING
finger family of proteins is that their functions, where known,
can be mediated through DNA binding. These functions
include regulation of gene expression, DNA recombination,
and DNA repair. Four proteins of the family are associated
with the regulation of development in Xenopus (XNF-7; ref.
29) or Drosophila [sina, ref. 30; Psc and Su(z)2, refs. 31 and
32]. DG17 (Dictyostelium; ref. 33) expression is also devel-
opmentally regulated. MEL18 (34) and BMI-I (35, 36) are
highly homologous human oncogenes (37). BMI-1 acts as a
cooperating oncogene with MYC in the acceleration of pre-
B-cell lymphomagenesis and the expressed protein is pre-
dominantly localized to the nucleus (35, 36). Mel18 protein is
also localized to the nucleus and has been shown to bind to
DNA-cellulose (34). Rpt-1 (mouse; ref. 38), PAS4 (yeast; ref.
63), and TLR (Trypanosoma brucei; refs. 39 and 40) have
been suggested to regulate gene expression with Rpt-l im-
plicated in down-regulation of the interleukin 2 receptor (38).
IEJ10 (41), VZ61 (42), CG30 (43), PE-38 (44), andEPO (45) are
viral early genes with known or suggested transactivation
properties. LCMV (46) and P11 (47) are related viral genes.
RAG-I (human; ref. 48) is involved in activation of DNA
recombination and RAD18 (yeast; ref. 49) is involved in DNA
repair. SS-A/Ro (human; ref. 50) gene product forms part of
a ribonucleoprotein complex, although there is no evidence
for direct nucleic acid interaction by SS-A/Ro. RET (51), T18
(52), and CBL (53) are known human oncogenes. RAD16
(yeast) has homology with proteins known to be involved in
chromatin structure and possesses a helicase domain motif
(64). The functions of the RING] (human) and PML (human;
refs. 54-57) genes are as yet unknown. Interestingly, PML is
disrupted and fused to the retinoic acid receptor a gene in
patients with acute promyelocytic leukemia (e.g., see ref. 56).
One unusual member of the family is peroxisome assembly
factor (PAF-1), which has been shown to promote the bio-
genesis ofperoxisomes (58). The presence ofthe RING finger
domain in PAF-1 could suggest that PAF-1 functions via
DNA interaction, although it does not exclude the possibility
that the PAF-1 RING finger has alternative properties.
To investigate the functional properties of the RING finger
motif, we have synthesized and purified a 55-amino acid
peptide (residues 12-66 in the RING1 sequence) correspond-
ing to the RING1 finger. The purity and sequence of the
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FIG. 2. Multiple sequence alignment of the
RING finger family. Identical residues are shown in
boldface. Metal binding ligands, which are abso-
lutely conserved between family members, are in-
dicated (*), as are the positions of conserved
hydrophobic residues ($). Numbering below each
conserved Cys refers to metal binding ligands Cysl-
Cys7. See text for reference to each sequence.
Amino acid insertions are indicated in parentheses.
Gaps have been inserted automatically by the AMPS
program to maximize sequence homology.
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synthetic peptide were confirmed by mass spectrometry and
solid-phase peptide sequencing. We then examined a range of
structural and functional properties of the peptide.
Metal Binding to the RING1 Finger. Divalent metal binding
properties of peptides and proteins can be determined by
studying the optical absorption spectra of specific cobalt-
peptide/protein complexes (21, 59-61). The RING1 peptide-
cobalt complex exhibits absorption maxima at A = 307 and
340-350 nm (Fig. 3A), which correspond to the S-Co(II)
charge transfer bands and indicate that the cysteines are
involved in metal binding. Several maxima are also observed
at A = 605, 655, and 690 nm, which correspond to the Co(II)
d-d transitions and are consistent with tetrahedral coordina-
tion ofthe cobalt by cysteine ligands. No spectral change was
observed during the cobalt titration. From direct titrations
with low peptide concentrations, the molar ratio of cobalt to
peptide at saturated binding is estimated as 1.8:1, which is in
general agreement with the predicted ratio of 2:1, as deter-
mined from the number of potential metal ligands. Cobalt
binding to the RING1 peptide is tighter than previously
observed for classical zinc finger peptides (Kd 1 ,uM; ref.
60), with a measured dissociation constant of 10 (±6) nM.
The preferential binding to the peptide of zinc over cobalt
is also shown in Fig. 3A. Increasing concentrations of zinc
diminish the intensities of the characteristic cobalt transi-
tions, even in 10-fold molar excess of cobalt over zinc. The
same experiment was carried out using iron, copper, man-
ganese, magnesium, and cadmium as the competitor metal to
cobalt (data not shown). No binding was observed for iron,
manganese, and magnesium. Some binding was observed for
copper but the binding was less tight than that for zinc.
However, cadmium bound as tightly as zinc, which has also
been observed for GAL4 (62). The RING1 finger therefore
binds zinc preferentially to other physiological divalent metal
ions and at least 10 times more tightly than cobalt, with a
dissociation constant in the nanomolar range.
Secondary Structure of the RING1 Finger. Preliminary
NMR studies of the reduced RING1 peptide showed the
peptide to be structured in the absence of zinc. Unexchanged
amide protons are observed in spectra of reduced RING1
peptide that has been freshly dissolved in 2H20, EDTA, and
DTT, indicating stable hydrogen bonding even in the absence
of zinc. However, upon addition of zinc the peptide under-
goes a conformational change as indicated by increased
aggregation and subsequent precipitation with resonances
shifting from their values in the reduced state (data not
shown). The extent of the conformational change will have to
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await a detailed NMR analysis, although we have no evi-
dence to suggest that the observed aggregation/precipitation
is caused by oligomerization.
CD studies of the reduced RING1 peptide in the absence
of zinc also show the peptide to be structured with =20o
a-helix and =20% p-sheet (Fig. 3B). The addition of zinc
causes a small but reproducible increase in ellipticity (Fig.
3B), consistent with a slight increase (c5%) in a-helix con-
tent. This suggests a possible structural rearrangement upon
zinc binding and could indicate a zinc-induced stabilization of
secondary structure. Our preliminary structural observations
ofthe RING1 peptide therefore suggest that the RING1 finger
has significant secondary structure in the absence of zinc, as
shown directly by NMR measurements, and that zinc binding
promotes a small conformational change.
DNA Binding of the RING1 Finger. The DNA binding
properties of the reduced RING1 peptide were analyzed by
gel mobility-shift assays using a 76-bp oligonucleotide con-
taining a central 26-bp randomized sequence (23) (Fig. 4). The
RING1 peptide retards the migration of the oligonucleotide
and forms one major discrete band in the presence of excess
zinc (Fig. 4A, lane 2). A number of fainter lower molecular
weight bands are also observed, which could represent
complexes with different ratios of peptide to DNA. Some
labeled DNA remains in the wells, which we attribute to
nonspecific aggregation. The retardation also appears to be
zinc dependent, as adding high concentrations of EDTA or
DTT diminishes the formation of the specific band (lanes
4-8). However, boiling and cooling the RING1 peptide-DNA
complex does not affect binding (lane 3), suggesting that the
"competent" peptide can refold into an active species.
Titration of the nonspecific competitor poly(dI-dC) against
the specific RING1 peptide-DNA complex shows inhibition
ofDNA retardation at a 1000-fold weight excess of compet-
itor to labeled DNA (Fig. 4B). From the titration, we measure
the association constant ofthe RING1 peptide for poly(dIdC)
to be in the micromolar range, which suggests that binding of
the peptide to poly(dI-dC) is nonspecific. However, it is clear
that the RING1 peptide binds to a subset ofrandomizedDNA
sequences at least 10-fold more tightly than to poly(dIdC), as
binding is unaffected in excess competitor (lanes 2 and 3).
Although a 100-fold molar excess of peptide to DNA was
used in the DNA binding reactions, we observed significant
peptide precipitation in the peptide-DNA reaction mixture
prior to loading the gel. We were therefore unable to deter-
mine the actual concentration of active peptide available for
DNA binding. However, it is clear that RING1-DNA com-
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FIG. 3. Physical characterization ofthe RING1 peptide. (A) Binding ofcobalt and zinc to the RING1 peptide. Spectrum for the peptide-cobalt
complex is shown as a solid line. Dashed lines represent spectra after addition of increasing amounts of zinc. (B) Effect of zinc on the far-UV
CD spectrum of the RING1 peptide. Spectra shown are unsmoothed averages of four scans.
Biochemistry: Lovering et al.
2116 Biochemistry: Lovering et al.
A B
amount ofpoly dl.dC
+ +
FIG. 4. DNA binding of the RING1 finger. (A) Zinc dependence
of RING1 peptide-DNA binding. Each lane contained 4 ;&g of
peptide, 200 pg of labeled oligonucleotide R76 DNA, and 260 ng of
poly(dIdC). Label above each lane refers to different conditions for
each of the binding reactions, with indicating standard conditions.
Lanes +, addition of 0.5 mM zinc sulfate, which was added to all but
one lane; lane -, binding reaction for peptide dissolved in zinc-free
binding buffer; lanes 5-8, dialyzed peptide was preincubated with
EDTA or DTT for 30 min before starting the binding reaction. (B)
Effect of nonspecific competitor concentration on RING1 peptide-
DNA binding. Each lane contained 4 jg of peptide and 200 pg of
labeled DNA. Increasing amounts of poly(dI.dC) were added to the
peptide-DNA as indicated.
plex formation is zinc dependent and that the complex is
unaffected by boiling. These results, however, do not provide
direct evidence for specific RING1 finger-DNA interaction
and furthermore do not exclude the possibility that the
RINGi finger binds to RNA preferentially.
In conclusion, spectroscopic studies show that the RING1
peptide is structured and binds zinc tightly with tetrahedral
coordination and that cysteines are involved in metal ligand-
ing. Preliminary gel-retardation studies provide evidence for
zinc-dependent DNA binding by the RINGl peptide. These
results support the proposal that the RING1 finger motif is a
zinc-dependent DNA binding domain found in this newly
defined family of proteins.
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